Fluzoparib is primarily used in the treatment of certain types of cancer, particularly ovarian cancer and other malignancies associated with BRCA mutations. It works by inhibiting the PARP enzyme, which plays a crucial role in DNA repair. By blocking PARP, the drug prevents cancer cells from repairing their DNA, leading to cell death. This targeted therapy is especially effective in patients with homologous recombination deficiency (HRD), as it exploits the inherent weakness in the cancer cells' ability to repair DNA damage. Fluzoparib is often administered as part of a combination therapy or as a maintenance treatment to prevent cancer recurrence after initial chemotherapy. Its use has shown promising results in improving progression-free survival and overall outcomes in patients with advanced or recurrent cancers.